Mobia Medical (NASDAQ:MOBI) Given Buy Rating at BTIG Research

Mobia Medical (NASDAQ:MOBI)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $19.00 price target on the stock. BTIG Research’s target price indicates a potential upside of 51.03% from the stock’s current price.

Other equities research analysts also recently issued research reports about the stock. Zacks Research upgraded shares of Mobia Medical to a “hold” rating in a research report on Wednesday, June 3rd. Bank of America assumed coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They set a “buy” rating and a $16.00 price target on the stock. Wolfe Research began coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. started coverage on Mobia Medical in a report on Tuesday, June 2nd. They set an “overweight” rating and a $15.00 price objective for the company. Finally, Wall Street Zen raised Mobia Medical from a “sell” rating to a “hold” rating in a research report on Sunday, June 14th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.25.

Mobia Medical Stock Down 1.2%

Shares of Mobia Medical stock opened at $12.58 on Wednesday. Mobia Medical has a 12-month low of $10.19 and a 12-month high of $15.29. The firm has a market capitalization of $418.27 million and a price-to-earnings ratio of -0.65. The stock’s fifty day moving average is $12.54.

Mobia Medical (NASDAQ:MOBI) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The company had revenue of $13.51 million during the quarter. Mobia Medical’s revenue was up 102.4% compared to the same quarter last year. As a group, equities analysts anticipate that Mobia Medical will post -2.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Nelson Bunker Curnes bought 5,000 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was purchased at an average price of $12.79 per share, with a total value of $63,950.00. Following the transaction, the chief financial officer directly owned 366,997 shares in the company, valued at approximately $4,693,891.63. The trade was a 1.38% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Key Mobia Medical News

Here are the key news stories impacting Mobia Medical this week:

• Positive Sentiment: Second-quarter revenue reached $13.5 million, up 102% year over year, while gross margin was a strong 83.2%. Management also reported durable two-year clinical benefits from its VNS-REHAB stroke-recovery therapy, including improvements in motor function, daily living activities and quality of life. Mobia Medical Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Mobia Medical raised approximately $134 million in net proceeds through its initial public offering, providing additional capital to support commercialization, research and corporate operations. Mobia Medical Q2 2026 Earnings Call Highlights
• Positive Sentiment: The company forecast 2026 revenue of $54 million to $56 million, representing approximately 69% to 75% growth and exceeding the roughly $53.5 million analyst consensus. Mobia Medical Forecasts 2026 Revenue
• Neutral Sentiment: Reported short-interest data showed zero shares sold short and a zero-day short-interest ratio, but the accompanying percentage change was listed as “NaN,” making the data unreliable and unlikely to provide a meaningful trading signal.
• Negative Sentiment: Mobia Medical reported a $1.10 per-share loss, wider than the expected $0.83 loss. The company remains unprofitable, and analysts expect a full-year loss of approximately $2.50 per share, which may keep pressure on the stock despite rapid top-line growth. Mobia Medical Quarterly Earnings Report

About Mobia Medical

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.